Indication:
GlympaTM is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Empagliflozin is indicated to reduce the risk of cardiovascular death in adults with type 2 diabetes mellitus and established cardiovascular disease.
Dosage & Administration:
The recommended dose is GlympaTM 10/ 5 once daily, taken in the morning, with or without food. Dose may be increased to GlympaTM 25/5 once daily.
Preparation:
GlympaTM Tablet: Each box contains 20 tablets in Blister pack.
GlympaTM Tablet: Each box contains 10 tablets in Blister pack.
